Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
IOVA
Iovance Biotherapeutics
$2.34
Login to see Iovance Biotherapeutics (IOVA) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Upgraded on attractively valued
Earnings are forecast to grow
Chart
$2.37 (-1.27%)
$2.01 (+16.42%)
$1.7 (+37.65%)
$10.24 (-77.15%)
IOVA has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Price under $5
High volatilty
IOVA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
IOVA Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
IOVA Street view is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayIOVA Earnings
The TTM reflects 12-month period, providing review of IOVA financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
What is IOVA current stock price?
What are IOVA stock strengths?
What risks are associated with IOVA stock?
When is IOVA next earnings report?
What is IOVA market cap and volume?
What is IOVA's current Stock IQ?
Should I buy IOVA stock right now?
Is IOVA a Strong Buy right now?
What does a 'Strong Buy' rating mean for IOVA?
What does a 'Strong Sell' rating mean for IOVA?
What factors influence IOVA's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
IOVA
Iovance Biotherapeutics
Current Price
$2.34
Stock Insights
Strengths
Upgraded on attractively valued
Earnings are forecast to grow
Login to unlock Iovance Biotherapeutics (IOVA) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$2.37 (-1.27%)
$2.01 (+16.42%)
$1.7 (+37.65%)
$10.24 (-77.15%)
IOVA Analysts Opinion
IOVA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
IOVA Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
IOVA Street view is extremely bullish and have negative views on the near-term outlook
IOVA has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Price under $5
High volatilty
Average key support and resistance price levels.
Login to displayIOVA Earnings
The TTM data reflects the most recent 12-month period, providing overview of IOVA financial performance.
IOVA Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
IOVA Latest Analysis
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4). SAN CARLOS Calif. Sept. 19 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics Inc. (NASDAQ: IOVA) (Iovance or the Company) a biotechnology company focused on innovating developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer today announced that on September 18 2025 (the Date of Grant) the Company approved the grant of inducement stock options covering a
Fri Sep 19, 2025
Can This Beaten-Down Stock Bounce Back?. Key PointsIovance Biotherapeutics cancer therapy Amtagvi is experiencing decent sales growth.
Fri Sep 19, 2025
Advancing Cancer Research Brings New Hope for Patients Worldwide. NetworkNewsWire Editorial CoverageOncotelic Therapeutics Inc. (OTCQB:) () distinguishes itself. Guided by the forward-looking leadership of chair and CEO Dr. Iovance Biotherapeutics Inc. (NASDAQ:) Merck &. Co. Inc. (NYSE:) AstraZeneca PLC (NASDAQ:) and Bristol-Myers Squibb Co. (NYSE:) — that are driving advances in these challenging therapeutic areas. At the forefront of Oncotelic'.s strategy is Dr. Oncotelic'.s flags
Wed Sep 17, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
IOVA Stock trends
IOVA Stock performance
IOVA Stock analysis
IOVA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings